(Q38293584)

1 September 2017

1 reference

title

Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives (English)

1 reference

1 September 2017

1 reference

Wolfram H Gerlich

1

1 reference

1 September 2017

19 December 2014

1 reference

Medical Microbiology and Immunology

1 September 2017

1 reference

1 September 2017

204

1 reference

1 September 2017

1

1 reference

1 September 2017

39-55

1 reference

https://scigraph.springernature.com/pub.10.1007/s00430-014-0373-y

1 September 2017

0 references

cites work

Medical virology of hepatitis B: how it began and where we are now

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis Virus: Effect of Heat on the Infectivity and Antigenicity of the MS-1 and MS-2 Strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Immunisation against hepatitis B in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

On the role of sexual behavior in the spread of hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Preparation and testing of a hepatitis B vaccine (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Inactivation of hepatitis B virus by three methods: treatment with pepsin, urea, or formalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Inactivation of 10(15) chimpanzee-infectious doses of hepatitis B virus during preparation of a heat-inactivated hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Immune response to hepatitis B vaccine in newborns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Summary statement of the Asilomar conference on recombinant DNA molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Cloning in Escherichia coli and physical structure of hepatitis B virion DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis B virus genes and their expression in E. coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Localization on the viral genome and nucleotide sequence of the gene coding for the two major polypeptides of the hepatitis B surface antigen (HBs Ag)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Partial amino acid sequence of two major component polypeptides of hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Expression of the hepatitis B virus surface antigen gene in cell culture by using a simian virus 40 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Viral hepatitis: global goals for vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Analysis of the microflora in the stomach of Mongolian gerbils infected with Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Immunogenicity of combined hepatitis A and B vaccine in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Chronic HBV infection among pregnant women and their infants in Shenyang, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: current standards of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Vaccine-induced escape mutant of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Nucleic acid testing to detect HBV infection in blood donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Statements from the Taormina expert meeting on occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Occult hepatitis B virus infection: detection and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Infectivity of blood products from donors with occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Further data on HBs antigen subtypes - geographical distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Genotypes and genetic variability of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Australia antigen (a hepatitis-associated antigen): purification and physical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis B antigen: antigenic sites related to human serum proteins revealed by affinity chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Biology of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Variable protein composition of hepatitis B surface antigen from different donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Demonstration of albumin receptors onisolated human hepatocytes by light and scanning electron microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

The role of envelope proteins in hepatitis B virus assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis B virus contains pre-S gene-encoded domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Viral and cellular determinants involved in hepadnaviral entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Infection of a human hepatoma cell line by hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Cell type specific expression of pre S 1 antigen and secretion of hepatitis B virus surface antigen. Brief Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

HBV core particles as a carrier for B cell/T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Electron microscopy of hepatitis B core antigen synthesized in E. coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0373-Y

Large surface proteins of hepatitis B virus containing the pre-s sequence

21 January 2018

1 reference

12 December 2020

DNA of a human hepatitis B virus candidate

1 reference

12 December 2020

Synthesis of hepatitis B surface antigen in mammalian cells: expression of the entire gene and the coding region

1 reference

12 December 2020

Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal)

1 reference

12 December 2020

Hepatitis B vaccine: efficacy in high-risk settings, a two-year study

1 reference

12 December 2020

A Receptor for polymerized human and chimpanzee albumins on hepatitis B virus particles co-occurring with HBeAg

1 reference

12 December 2020

Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program

1 reference

12 December 2020

Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines

1 reference

12 December 2020

Production of purified hepatitis B surface antigen from Alexander hepatoma cells grown in artificial capillary units

1 reference

12 December 2020

Australia Antigen: Large-Scale Purification from Human Serum and Biochemical Studies of Its Proteins

1 reference

12 December 2020

Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine

1 reference

12 December 2020

Viral hepatitis, type B (MS-2 strain). Studies on active immunization

1 reference

12 December 2020

Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination

1 reference

12 December 2020

Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients

1 reference

12 December 2020

Increased prevalence of HBV envelope mutants in Taiwan: an emerging public health risk or a false alarm?

1 reference

12 December 2020

Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine

1 reference

12 December 2020

1 reference

12 December 2020

Simultaneous expression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha

1 reference

12 December 2020

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

1 reference

12 December 2020

Safety and potency aspects in the preparation of an experimental HBsAg vaccine

1 reference

12 December 2020

Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial.

1 reference

12 December 2020

Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation

1 reference

12 December 2020

Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products

1 reference

12 December 2020

Comparative biophysical studies of hepatitis B antigen, subtypes adw and ayw

1 reference

12 December 2020

Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines

1 reference

12 December 2020

[Hepatitis-associated antigen: purification and properties]

1 reference

12 December 2020

A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults

1 reference

12 December 2020

A hepatitis B surface antigen polypeptide (P31) with the receptor for polymerized human as well as chimpanzee albumins

1 reference

12 December 2020

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

1 reference

12 December 2020

Expression of hepatitis B virus middle and large surface antigen genes in Saccharomyces cerevisiae.

1 reference

12 December 2020

Toward elimination and eradication of hepatitis B.

1 reference

12 December 2020

Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees.

1 reference

12 December 2020

To have B or not to have B: vaccine and the potential eradication of hepatitis B

1 reference

12 December 2020

Towards the eradication of hepatitis B in Taiwan

1 reference

12 December 2020

Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection

1 reference

12 December 2020

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

1 reference

12 December 2020

Proteins of hepatitis B surface antigen

1 reference

12 December 2020

A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine

1 reference

12 December 2020

Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers

1 reference

12 December 2020

Hepagene (PowderJect).

1 reference

12 December 2020

Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial

1 reference

12 December 2020

Establishment of a continuously growing cell line from primary carcinoma of the liver

1 reference

12 December 2020

Purified and inactivated human hepatitis B vaccine: progress report

1 reference

12 December 2020

Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial

1 reference

12 December 2020

Kinetics, subtype specificity and immunoglobulin class of anti-HBs induced by hepatitis B vaccine

1 reference

12 December 2020

Development and chimpanzee testing of a vaccine against human hepatitis B.

1 reference

12 December 2020

Presence of anti-preS1, anti-preS2, and anti-HBs antibodies in newborns immunized with Bio-Hep-B vaccine

1 reference

12 December 2020

Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination

1 reference

12 December 2020

Hepatitis: Global eradication of hepatitis B--feasible or fallacy?

1 reference

12 December 2020

Structural relationships between minor and major proteins of hepatitis B surface antigen.

1 reference

12 December 2020

Expression of hepatitis B surface antigen in yeast

1 reference

12 December 2020

Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency

1 reference

12 December 2020

10.1007/S00430-014-0373-Y

Identifiers

DOI

1 reference

PubMed ID

25523195

Dimensions Publication ID

1 September 2017

0 references

1 reference

PubMed ID

25523195